Company news
Cullinan Therapeutics, Inc. news in 2023
Cullinan Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 17, 2023
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
December 13, 2023
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 7, 2023
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
November 2, 2023
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 9, 2023
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
August 8, 2023
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
August 2, 2023
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
May 24, 2023
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 10, 2023
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
April 25, 2023
Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days
April 19, 2023
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines
March 26, 2023
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting
March 13, 2023
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 8, 2023
Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference
February 26, 2023
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed
February 12, 2023
Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference
February 1, 2023
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2023
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
January 23, 2023